Universal reference book for medicines
Product name: VAZOBRAL ®

Active substance: alpha-dihydroergocryptine, caffeine

Type: A drug that improves cerebral and peripheral circulation

Manufacturer: CHIESI (France)
Composition, form of production and packaging
The solution for oral administration
is clear, colorless or pale yellow, with the smell of alcohol.

1 ml

alpha-dihydroergocriptine mesylate 1 mg

caffeine 10 mg

Excipients: citric acid, ethanol, glycerol, purified water.

50 ml - bottles of dark glass (1) complete with a dispensing syringe - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2014.

PHARMACHOLOGIC EFFECT

The combined preparation,? -dihydroergocriptine - the dihydrated ergot derivative, blocks?
1 and? 2- adrenoreceptors. It has a dopaminergic, serotonergic effect, reduces platelet and erythrocyte aggregation, reduces the permeability of the vascular wall, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, increases the resistance of brain tissue to hypoxia.
Caffeine has a psychostimulating and analeptic effect, enhances the processes of excitation in the cerebral cortex - increases mental and physical performance, reduces fatigue and drowsiness, increases the reflex excitability of the spinal cord, excites the respiratory and vasomotor centers, and has a diuretic effect.

PHARMACOKINETICS

When taken orally, the absorption of dihydroergocryptin is accelerated in the presence of caffeine (the time to reach the maximum concentration in the blood plasma is 0.5 hours).

The maximum concentration after ingestion of 8 mg of β-dihydroergocryptin is 227 pg / ml, and the elimination half-life is less than 2 hours.

INDICATIONS

- reduction of mental activity, violation of attention and memory, violation of orientation in space, caused by age-related changes;

- cerebrovascular insufficiency (including due to cerebral atherosclerosis);

- consequences of cerebrovascular accident;

- prevention of migraine;

- Vestibular and labyrinthine disorders (dizziness, tinnitus, hypoacusia) ischemic origin;

- Ménière's disease;

- retinopathy (diabetic and hypertensive);

- violations of peripheral arterial blood circulation (syndrome and Raynaud's disease);

- Venous insufficiency.

DOSING MODE

Inside (during meals, with a small amount of liquid) for 2-4 ml (1-2 dosing syringe) 2 times a day.
The duration of the course of treatment is 2-3 months, if necessary, treatment courses can be repeated.
SIDE EFFECT

From the gastrointestinal tract: nausea, gastralgia, dyspepsia, with these manifestations, the drug is not required to be withdrawn.

Rarely (no more than 1% of cases) - dizziness, agitation, headache.

Very rarely (not more than 0.1% of cases) are possible allergic reactions, tachycardia, lowering blood pressure.

CONTRAINDICATIONS

- increased individual sensitivity to the components of the drug.

PREGNANCY AND LACTATION

There are no clinical data on the use of Vazobrala during pregnancy and lactation.

The use of the drug in the period of breastfeeding can lead to a decrease in lactation.

SPECIAL INSTRUCTIONS

Vasobrail has a vasodilating effect, without affecting the systemic blood pressure.
The appointment of Vasobrail to patients with arterial hypertension does not preclude the use of antihypertensive agents. The caffeine contained in the preparation can cause sleep disturbances, tachycardia.
OVERDOSE

Symptoms - increased severity of side effects.
Treatment is symptomatic.
DRUG INTERACTION

With the simultaneous appointment of Vasobrail and hypotensive drugs, it is possible to develop arterial hypotension.
Caffeine weakens the effect of hypnotics.
TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

At a temperature of 15-25 ° C, out of reach of children.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!